CLINUVEL PHARMACEUTICALS
Generated by Meeveem AI
"Translates melanocortin science into treatments for patients with no alternatives"
Melbourne, VIC
•51 - 250 Employees
•Pharmaceuticals
About CLINUVEL PHARMACEUTICALS
CLINUVEL develops pharmaceutical treatments and luxury skincare through expertise in melanocortin peptides and photomedicine. The company focuses on patients with genetic, metabolic and life threatening disorders affecting skin and brain where no treatment alternatives exist. Its lead therapy, SCENESSE, is the world's first systemic photoprotective drug approved for erythropoietic protoporphyria. The publicly traded group operates from Melbourne with offices across Europe, Singapore and the United States. Research spans systemic photoprotection, DNA repair and repigmentation. The PhotoCosmetics division applies pharmaceutical science to develop skincare with polychromatic light protection.
52
Team Members
1999
Founded
Pharmaceuticals
Sector
Hybrid
Work Environment
Our Vision
A world where patients with rare genetic disorders and acute conditions affecting skin and brain receive effective, scientifically proven treatments that restore quality of life and prevent suffering.
Our Mission
The CLINUVEL Group works to translate scientific concepts and breakthroughs into commercial products to prevent or treat acute and chronic medical conditions where no alternatives exist.